期刊文献+

LC-MS法测定Beagle犬血浆中埃博霉素B及其药动学研究 被引量:1

Pharmacokinetic study of epothilone B in Beagle dog plasma by LC-MS
原文传递
导出
摘要 目的建立液相色谱串联质谱(LC-MS)法测定Beagle犬血浆中埃博霉素B含量,分析埃博霉素B在Beagle犬体内的药动学参数。方法采用LC-MS方法测定Beagle犬接受0.05,0.10和0.15 mg/kg埃博霉素B静脉给药后不同时间点的血浆浓度,药物浓度-时间数据通过DAS2.0版软件进行分析。结果血浆中埃博霉素B在0.1~18 ng/mL浓度范围内线性关系良好(r=0.9999),血浆中样品提取回收率大于70%,日内和日间的精密度(RSD)均小于15%。药动学参数t_(1/2β)分别为(76.20±7.24)、(71.41±10.62)和(64.62±9.76)h,AUC_(0-∞)分别为(43.89±7.95)、(95.16±20.82)和(127.43±31.41)μg/(L·h)。结论 LC-MS测定方法操作简便,专属性强,灵敏度高,适用于Beagle犬体内埃博霉素B的浓度测定和药动学研究。Beagle犬静脉注射3个剂量埃博霉素B后的药物浓度-时间数据符合二室模型特征,日族博霉素B在犬体内半衰期较长。 Objective Through LC-MS method to detect epothilone B in Beagle dog plasma and to perform its pharmacokinetics. Methods The plasma concentration of epothilone B was determined at different time points by LC- MS, after a single i.v. injection of 0.05, 0.10, and 0.15 mg/kg to Beagle dogs respectively. Processed data were treated by software DAS 2.0. Results The method was linear over the range of 0.1 - 18 ng/mL (r=0.9999), the recovery of epothilone B in dog plasma was more than 70% and the relative standard (RSD) ofintra-and inter-batch precision was less than 15%. The main pharmacokinetic parameters at three concentrations were as follows: t1/2β (76.20±7.24, 71.41±10.62, 64.62± 9.76)h, AUCo-∞ (43.89±7.95, 95.16±20.82,127.43±31.41)μg/(L. h ), respectively. Conclusion The LC-MS is a simple, sensitive and specific method for determination of epothilone B in Beagle dog plasma and its pharmacokinetic study. The data of concentration versus time fitted the two-compartmental model after i.v. injection three doses of epothilone B in Beagle dog, and drug half-life was longer in vivo.
出处 《世界临床药物》 CAS 2012年第9期539-543,共5页 World Clinical Drug
关键词 埃博霉素B BEAGLE犬 药动学 液相色谱串联质谱(LC—MS) epothilone B Beagle dog pharmacokinetics liquid chromatography-mass spectrometry (LC-MS)
  • 相关文献

参考文献6

  • 1Hoefle G, Steinmetz H, Bedorf N, et al. Epothilone A and B - novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution [J]. Angew Chem Int Ed Engl, 1996, 35 (13-14) : 1567-1569.
  • 2Muehlradt PF, Sasse F. Epothilone B stablizes microtubule of maerophages like taxol without showing taxol-like endo toxin activity[J]. Cancer Res, 1997, 57 (16): 3344-3346.
  • 3Buey RM, Diaz JF, Andreu JM, et al. Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity EJ]. Chem Biol, 2004, 11 (2): 225-236.
  • 4Reese M, Sanchez-Pedregal VM, Kubicek K, et al. Structural basis of the activity of the microtubule-stabilizing agent epothilone A studied by NMR spectroscopy in solution [J]. Angew Chem Int Ed Engl, 2007, 46 (11): 1864-1868.
  • 5Rothermel J, Wartmann M, Chen T, et al. EPO906 (epothilone B) : a promising novel microtubule stabilizer E J]. Semin Oncol, 2003, 30 (3 Suppl 6): $51-$55.
  • 6O'Reilly T, Wartmann M, Brueggen J, et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor- bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo [J]. Cancer Chemother Pharmacol, 2008, 62 (6) : 1045-1054.

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部